| PRASUGREL HYDROCHLORIDE | Eli Lilly | ||
| 5mg, 10mg; Tablet, Oral |
Less Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
Less Than 5
|
None | ||
|
More Than 5
|
More Than 5
|
||
| To reduce risk of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with percutaneous coronary intervention (patients with unstable angina | |||
|
Yes
| |||
| Effient | Patent 1 | Patent 2 | Patent 3 |
|---|---|---|---|
| *** ****** | ******* | ******* | ******* |
| ****** (*****) | ******* | ******* | ******* |
| ********* | ******* | ******* | ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** ****** | *** \ ** | **** **, **** | ******* | **** | ****** **** ******** |
| ****** (*****) | ** \ ** | **** **, **** | ******* | ******** | ******** ** *** **** |
| ********* | ** \ ** | **** **, **** | ******* | ******** | ******** ** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|